• 1
    Lok ASF, McMahon BJ. Practice guidelines. Chronic hepatitis B: update. Hepatology 2009; 50: 136.
  • 2
    Afdhal N, Buti M, Fung S, Gane E, Martins E, Bekele N, et al. Factors associated with regression of cirrhosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver, April 18–22, 2012. Poster Number 497.
  • 3
    Chang T-T, Liaw Y-F, Wu S-S, Schiff E, Han K-H, Lai C-L, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886893.
  • 4
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 5
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424432.
  • 6
    Fontana Rj, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719727.
  • 7
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349360.
  • 8
    Liaw YF, Raptopoulou-Gigi M, Cehinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatol 2011; 54: 91100.
  • 9
    Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing W, et al. Tenofovir disoproxil fumurate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 6272.
  • 10
    Huang K, Hu J-H, Wang H-F, He W-P, Chen J, Duan X-Z, et al. Survival and prognostic factors in hepatitis B virus-related acute on chronic liver failure. World J Gastroenterol 2011; 17: 34483452.
  • 11
    Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774780.
  • 12
    Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256263.
  • 13
    Kumar M, Satapathy S, Mnga RE, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 9710.
  • 14
    Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 2012; 57: 13491357.
  • 15
    Dao DY,HynanLS Sanders C, Balko J, Attar N, Lok ASF, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatol 2012; 55: 676684.